La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Dimerix Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Dimerix.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	14.6%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Dimerix non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

ASX:DXB - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	9	-17	-7	-7	N/A
3/31/2024	9	-14	-3	-3	N/A
12/31/2023	9	-11	1	1	N/A
9/30/2023	9	-12	-6	-6	N/A
6/30/2023	9	-14	-13	-13	N/A
3/31/2023	8	-14	-12	-12	N/A
12/31/2022	6	-14	-11	-11	N/A
9/30/2022	6	-12	-12	-12	N/A
6/30/2022	6	-10	-13	-13	N/A
3/31/2022	5	-10	-12	-12	N/A
12/31/2021	4	-9	-11	-11	N/A
9/30/2021	4	-7	-9	-9	N/A
6/30/2021	4	-6	-6	-6	N/A
3/31/2021	3	-6	-5	-5	N/A
12/31/2020	2	-6	-4	-4	N/A
9/30/2020	2	-5	-5	-5	N/A
6/30/2020	2	-4	-5	-5	N/A
3/31/2020	2	-4	-4	-4	N/A
12/31/2019	1	-4	-4	-4	N/A
9/30/2019	1	-4	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	1	-3	-3	-3	N/A
12/31/2018	1	-3	-3	-3	N/A
9/30/2018	1	-3	-3	-3	N/A
6/30/2018	1	-3	-3	-3	N/A
3/31/2018	1	-3	N/A	-3	N/A
12/31/2017	1	-3	N/A	-2	N/A
9/30/2017	1	-2	N/A	-2	N/A
6/30/2017	1	-2	N/A	-2	N/A
3/31/2017	1	-2	N/A	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	1	-3	N/A	-2	N/A
6/30/2016	1	-5	N/A	-1	N/A
3/31/2016	0	-5	N/A	-1	N/A
12/31/2015	0	-5	N/A	-1	N/A
9/30/2015	0	-3	N/A	-1	N/A
6/30/2015	0	-1	N/A	-1	N/A
4/30/2014	0	0	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista DXB è superiore al tasso di risparmio ( 2.4% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di DXB cresceranno più velocemente del mercato Australian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di DXB cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di DXB cresceranno più rapidamente del mercato Australian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di DXB cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di DXB è previsto essere elevato tra 3 anni

Dimerix Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Dimerix Limited, Annual General Meeting, Oct 01, 2024

Non Executive Director exercised options to buy AU$70k worth of stock.

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

New major risk - Share price stability

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.20

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.46

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita